National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 460993

Case Details

VAERS ID: 460993 (history)  
Form: Version 1.0  
Age: 0.2  
Sex: Unknown  
Location: California  
Submitted: 2012-07-31
Entered: 2012-08-03
   Days after submission:3
Vaccin­ation / Manu­facturer Lot / Dose Site / Route

Administered by: Unknown       Purchased by: Unknown
Symptoms: Death, Pertussis

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 0000-00-00
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: The infant had a premature birth at 28 weeks gestation. No other medical history was reported.
Diagnostic Lab Data: Not reported.
CDC Split Type: 201207246

Write-up: Initial case received via search of scientific literature on 26 July 2012. The following is verbatim from the article abstract: "Objective: In 2010, an area experienced the highest number of pertussis cases in $g60 years, with $g9000 cases, 809 hospitalizations, and 10 deaths. This report provides a descriptive epidemiologic analysis of this epidemic and describes public health mitigation strategies that were used, including expanded pertussis vaccine recommendations. STUDY DESIGN: Clinical and demographic information were evaluated for all pertussis cases with onset from January 1, 2010 through December 31, 2010, and reported to the Department of Public Health. RESULTS: Infants younger than 6 months had the highest disease rates; all deaths and most hospitalizations occurred in infants younger than 3 months. Most pediatric cases were vaccinated according to national recommendations, although 9% of those aged 6 months to 18 years were completely unvaccinated against pertussis. High disease rates also were observed in fully vaccinated preadolescents, especially 10-year-olds. Mitigation strategies included expanded tetanus, diphtheria, and acellular pertussis vaccine recommendations, public and provider education, distribution of free vaccine for postpartum women and contacts of infants, and clinical guidance on diagnosis and treatment of pertussis in young infants. CONCLUSIONS: Infants too young to be fully vaccinated against pertussis remain at highest risk of severe disease and death. Data are needed to evaluate strategies offering direct protection of this vulnerable population, such as immunization of pregnant women and of newborns. The high rate of disease among preadolescents suggests waning of immunity from the diphtheria, tetanus, and acellular pertussis series; additional studies are warranted to evaluate the efficacy and duration of protection of the diphtheria, tetanus, and acellular pertussis series and the tetanus, diphtheria, and acellular pertussis series." The following is verbatim from the article: "The remaining fatality was a 2-month-old infant born prematurely at 28 weeks gestational age who had received the first dose of diphtheria, tetanus, and accelular pertussis (DTaP) vaccine 15 days prior to disease onset." A two-month-old infant (date of birth and gender not reported), who was born at 28 weeks gestation, received dose one injection of DTaP, manufacturer unknown, (lot number, route and site not reported) on an unspecified date. On an unspecified date, 15 days after vaccination, the patient developed Pertussis. Other than premature birth, the patient''s past medical history, concomitant medications or vaccinations were not reported. Hospitalization, laboratory/diagnostic studies, treatments and date of death were not reported. The patient''s outcome was reported as fatal. Documents held by sender: None.

New Search

Link To This Search Result:

Copyright © 2020 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166